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Are advanced oxidation protein products potential uremic tox- complex [2]. Likewise, activated MN also release these
ins? Oxidative stress, defined as a disruption of the equilibrium compounds, although at much lower rates than PMN,
between the generation of oxidants and the activity of anti- and are mainly endowed with the production of the po-oxidant systems, plays a significant role in the development
tent pro-inflammatory cytokines IL1, TNF-, and IL-6.of the inflammatory syndrome associated with chronic renal
In addition to the formation of NADPH oxidase-failure and hemodialysis. In our recent work, the aim of which
was to better characterize oxidative stress in dialysis patients, derived ROS, phagocytic cells have the capacity to pro-
we described the presence of oxidized protein products, which duce chlorinated oxidants via the myeloperoxidase
we have termed advanced oxidation protein products (AOPP),
(MPO) system, which, in the presence of chloride ions,in the plasma of dialysis patients and we proposed AOPP as
converts H2O2 into hypochlorous acid (HOCl). In hu-new markers of oxidative stress and potential inflammatory
mediators. AOPP represent an exquisite marker of phagocyte- mans, MPO is the sole enzyme capable of generating
derived oxidative stress, and their role in the pathophysiology such microbicidally-chlorinated oxidants [3]. However,
of chronic renal failure and dialysis-related complications might more recent work on MPO has clearly shown that MPO
be of great importance. Regarding the mechanisms of genera-
is implicated in the inflammatory process associated withtion of AOPP, we pointed out the importance of myeloperoxi-
atherosclerosis since MPO is detected in aortic athero-dase and the subsequent generation of chlorinated oxidants,
previously considered solely as microbicidal agents, in the for- matous plaques, but not in normal aortae [4, 5].
mation of AOPP. Indeed, AOPP appear to act as true inflam- In the dialysis patient, the pro-inflammatory effects of
matory mediators since they are able to trigger the oxidative these oxidants, proteases, and cytokines are reinforcedburst and the synthesis of inflammatory cytokines in neutro-
by the uremia-associated defect in anti-oxidant systemsphils, as well as in monocytes. Thus, it could be hypothesized
that the AOPP, which arise from the reaction between chlori- [6], anti-proteases [7], and cytokine inhibitors [8]. Recent
nated oxidants and plasma proteins, constitute new uremic studies have clearly demonstrated that inflammation, to-
toxins with pro-inflammatory effects. gether with malnutrition, largely contributes to the accel-
erated atherosclerosis process of uremia, which still rep-
resents the leading cause of mortality in HD patients [9].
The presence of a chronic inflammatory state, which
is, to a large extent, induced by an oxidative stress subse-
quent to disruption of the natural balance between the DESCRIPTION OF ADVANCED OXIDATION
generation of oxidants and the activity of anti-oxidant PROTEIN PRODUCTS IN UREMIA
systems, has been widely documented in end-stage renal Until recently, biological evidence of oxidative stress
disease patients on maintenance hemodialysis (HD) [1]. in the dialysis patient in vivo relied almost entirely on
The oxidative stress is commonly attributed to the recur- the measurement of lipid peroxidation by-products, such
rent activation of polymorphonuclear neutrophils (PMN) as malondialdehyde and thiobarbituric acid reactive sub-
and monocytes (MN) during blood passage through stances (TBARS), which, in general, poorly reflect the
dialysis circuits, and subsequent generation of activated intensity of oxidative stress. The exquisite vulnerability
complement components following contact with bioincom- of proteins to ROS is now well documented [10]. Oxida-
patible membranes and/or possible transfer of endotox- tion of amino acid residues such as tyrosine, which leads
ins from the dialysate. Activated PMN generate the cas- to the formation of dityrosine, protein aggregation,
cade of highly reactive oxygen species (ROS) (e.g., O2 , cross-linking, and fragmentation are but a few examples
H2O2, and OH) which results from NADPH oxidase of ROS-mediated protein damage in vitro. In contrast,
evidence for the presence of such oxidatively-damaged
Key words: inflammation, phagocyte, myeloperoxidase. proteins in vivo and their possible clinical significance
has been lacking until recently. In the search whether 2003 by the International Society of Nephrology
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such protein oxidative damage could reflect the dialysis- decrease AOPP levels, thus revealing that they are de-
void of oxidant activity. However, the precise chemicalassociated oxidative stress, we were able to isolate and
characterize dityrosine-containing protein cross-linking structure of plasma AOPP has still not been elucidated.
Our recent data indicate that in vivo plasma AOPP mightproducts in the plasma of dialysis patients; these we desig-
nated as advanced oxidation protein products (AOPP) in not be identical to in vitro HOCl-treated plasma, and
more complicated reactions might occur in vivo. Likereference to the well-established advanced glycation end
products (AGEs), to which AOPP appeared to be closely AGEs, AOPP represent a generic name for oxidatively-
modified proteins, especially via the myeloperoxidaserelated [11]. The formation of AGEs has been widely
documented during diabetes and aging, and is thought system. The methodology to determine plasma AOPP
is well characterized and several groups have now con-to be responsible for tissue degradation. The presence
of increased plasma levels of AGEs has been observed firmed the high AOPP levels in HD patients [15] and
in other oxidative stress-related pathologies [16]. Thisin dialysis patients, independent of diabetes [12]. Inter-
estingly, the hypothesis that oxidative stress is implicated methodology relies on their spectrophometric proper-
ties, which are the absorbance at 340 nm in acidic condi-in AGEs formation might also be relevant to the uremic
toxicity syndrome. We reported that the well-character- tions, as previously described.
ized AGEs pentosidine accumulates with progression of
The plasma concentration of the toxin should bechronic renal failure in close relationship with neopterin,
higher in uremic than in nonuremic patientsa well-characterized monocyte activation marker.
We showed that increased levels of AOPP are already
observed at an early stage of chronic renal failure (CRF),
ARE AOPP UREMIC TOXINS?
and rise with the progression of uremia. Our previous
The contribution of uremia to chronic inflammatory data have clearly shown that plasma levels of AOPP
state has been suggested and numerous studies have were significantly higher in predialysis CRF patients than
shown that both monocyte activation and defect in anti- in control groups and culminated in HD patients. Among
oxidant systems occur early in the course of chronic renal predialysis patients, an inverse relationship between
failure and gradually increase with its progression to plasma AOPP and creatinine clearance (Ccr) levels was
end-stage renal disease. Interest has focused on the role found. Interestingly, AOPP levels are closely related to
of uremic toxins generated during the course of chronic plasma levels of monocyte activation markers such as
renal failure, some of which have known effects on neu- neopterin, TNF-, and its soluble receptors. There was
trophil and monocyte functions. Among these, AGEs no correlation with IL-6 and no correlation with markers
have been the focus of numerous studies. In the search of activated T cells (soluble IL-2 receptors) or B cells
whether AOPP could act as a uremic toxin, we have (soluble CD23) [17].
spent some effort during the last 10 years to determine
The compound must be a chemical or biological agentif AOPP could meet the criteria that characterizes a
capable of interacting with biological systems anduremic toxin, according to Vanholder et al [13].
produce a deleterious biological response
The compound should be chemically identified, and The study of the relationship between AOPP and neu-
accurate quantitative analysis in biological fluids trophil oxidative metabolism showed that neutrophil
should be possible basal NADPH oxidase activity (as measured by luci-
Size exclusion chromatography of uremic plasma al- genin-amplified chemiluminescence [CL]) was within the
lowed us to isolate high–molecular-weight AOPP (600 range of controls, regardless of the stage of CRF in
kD), which are protein aggregates, and low–molecular- predialysis patients, but was significantly increased in
weight compounds (around 80 kD), with albumin as a HD patients. Likewise, neutrophil MPO activity (as mea-
main component. Isolation of the two main plasma frac- sured by luminol-amplified CL) remained within the nor-
tions containing the two distinct AOPP peaks [11] has mal range in predialysis patients, regardless of the degree
been reproduced by other groups [14]. Biochemical char- of CRF, but was markedly higher in HD patients. These
acteristics allow us to consider AOPP as final cross-link- data strongly suggest that neutrophil oxidative potential
ing products of protein oxidation. Compared with con- is involved in plasma AOPP formation.
trols, AOPP were found at very high concentrations in In vitro studies showed that AOPP could be generated
the plasma of dialysis patients and were closely related by exposing proteins such as human serum albumin
to dityrosine, a marker of protein oxidation. In vitro, (HSA) to oxidants, among which HOCl was found to
exposure of control plasma or purified plasma albumin be the most powerful. We have previously shown that
to chlorinated oxidants triggered the formation of AOPP HSA-AOPP has the ability to trigger an oxidative burst
in an oxidant concentration-dependent manner. Anti- in neutrophils as well as in monocytes. Interestingly, the
intensity of the respiratory burst is dependent on theoxidants such as ascorbic acid or glutathione did not
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Fig. 1. Intracellular detection of IL-8 in PMN
and TNF- in MN stimulated with AOPP. PMN
and MN were isolated from blood of healthy
donors. Cells were stimulated with appropriate
stimuli to induce cytokine production and intra-
cellular IL-8 or TFN- were measured by flow
cytometry after cell permeabilization as indi-
cated by the manufacturer (Becton Dickinson).
(A ) PMN (106 cells/ml) were stimulated either
with purified human serum albumin (HSA at
10 mg/ml) or with different concentrations of
AOPP for 15 hours. (B ) MN (0.5 106 cells/ml)
were stimulated overnight either with purified
human serum albumin (HSA at 10 mg/ml) or
with AOPP or with LPS.
level of protein oxidation. The respiratory burst was thickness (CCA-IMT) and CCA wall-to-lumen ratio in
uremic patients. AOPP levels were also positively corre-triggered by different preparations of AOPP obtained
lated with ferritin levels and the dose of intravenouswith various ratios of HSA/HOcl [17]. More recently,
iron administered. Interestingly, there was no correlationwe have shown that AOPP purified from uremic plasma
between other oxidative stress markers, such as malon-also trigger the respiratory burst of normal neutrophils.
dialdehyde (MDA), and with cardiovascular parameters.Recently, we observed that AOPP were potent stimuli
These findings support the concept of a role of phago-in triggering interleukin-8 synthesis in neutrophils, as
cyte-derived oxidative stress in the accelerated athero-shown in Fig. 1A. We were able to show by flow cytome-
sclerosis of uremic patients, which may be enhanced bytry analysis that marked IL-8 synthesis occurs 12 hours
usual recommended doses of intravenous iron [19]. Thisfollowing AOPP stimulation, and that it is potentiated
study points out the relevance of AOPP follow-up in theby GM-CSF. Interestingly, HSA-AOPP was also able to
management of uremia patients in their assessment for
trigger the synthesis of inflammatory cytokines in mono- cardiovascular risk factors.
cytes, such as TNF- (Fig. 1B).
CONCLUSIONHigh concentrations should be related to specific
uremic syndroms that decrease or disappear In conclusion, we propose that AOPP generated via
when the concentration is reduced the MPO system could not only be exquisite markers of
the oxidative stress, but also active mediators of theSo far, no study has been performed to see whether
inflammation associated with the uremic state. AOPPpharmacologic modulation of AOPP could improve the
appear to meet the criteria of a novel uremic toxin.inflammatory state associated with uremia. However, we
Neutrophils and monocytes, which could themselves am-have recently described that, in vitro, N-acetylcysteine
plify the inflammatory process by increasing the neutro-could selectively decrease AOPP-induced respiratory
phil recruitment via enhanced IL-8 synthesis and oxidantburst without any effect on zymosan-induced respiratory
generation, appear to be elective targets of AOPP. These
burst in purified neutrophils. This was observed both in observations lead us to propose that AOPP are key mole-
neutrophils from control groups and from hemodialyzed cules in the cross-talk between these two types of phago-
patients [18]. This potential pathway for modulating an cytes. It is plausible that they make a large contribution
AOPP-induced pro-inflammatory effect has yet to be to the immune dysregulation and inflammatory process
explored in vivo. in uremia.
AOPP belong to the compounds that could play a role
in the development of cardiovascular complications. In ACKNOWLEDGMENT
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